Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
Psyence BioMed (NASDAQ: PBM) has announced a USD $500,000 follow-on investment in PsyLabs, strengthening their partnership in psychedelic medicine development. This builds upon their September 2024 agreement where PBM acquired an 11.13% equity stake in PsyLabs.
The investment includes two key components:
- An exclusive, royalty-bearing IP licensing agreement for pharmaceutical-grade, EU-GMP, nature-derived psilocybin supply
- An exclusive right of first refusal for worldwide supply of pharmaceutical-grade, nature-derived Ibogaine
The partnership focuses on developing treatments for Substance Use Disorders (SUD), including Alcohol Use Disorder (AUD). PsyLabs will provide Psyence BioMed with high-quality psychedelic compounds to support their clinical pipeline and therapeutic development efforts. The deal is subject to definitive agreements and regulatory approvals.
Psyence BioMed (NASDAQ: PBM) ha annunciato un investimento aggiuntivo di 500.000 USD in PsyLabs, rafforzando la loro collaborazione nello sviluppo di medicine psichedeliche. Questo segue l'accordo di settembre 2024, quando PBM ha acquisito una quota azionaria dell'11,13% in PsyLabs.
L'investimento comprende due elementi chiave:
- Un accordo esclusivo di licenza IP con royalty per la fornitura di psilocibina di grado farmaceutico, derivata dalla natura e conforme agli standard EU-GMP
- Un diritto esclusivo di prelazione per la fornitura mondiale di ibogaina di grado farmaceutico, derivata dalla natura
La partnership si concentra sullo sviluppo di trattamenti per i Disturbi da Uso di Sostanze (SUD), incluso il Disturbo da Uso di Alcol (AUD). PsyLabs fornirà a Psyence BioMed composti psichedelici di alta qualità per supportare il loro pipeline clinico e gli sforzi di sviluppo terapeutico. L'accordo è soggetto a intese definitive e approvazioni regolatorie.
Psyence BioMed (NASDAQ: PBM) ha anunciado una inversión adicional de 500.000 USD en PsyLabs, fortaleciendo su colaboración en el desarrollo de medicamentos psicodélicos. Esto se basa en el acuerdo de septiembre de 2024, cuando PBM adquirió una participación accionaria del 11,13% en PsyLabs.
La inversión incluye dos componentes clave:
- Un acuerdo exclusivo de licencia de propiedad intelectual con regalías para el suministro de psilocibina de grado farmacéutico, derivada de la naturaleza y conforme a estándares EU-GMP
- Un derecho exclusivo de tanteo para el suministro mundial de ibogaína de grado farmacéutico, derivada de la naturaleza
La asociación se centra en el desarrollo de tratamientos para Trastornos por Uso de Sustancias (SUD), incluido el Trastorno por Uso de Alcohol (AUD). PsyLabs proporcionará a Psyence BioMed compuestos psicodélicos de alta calidad para apoyar su pipeline clínico y los esfuerzos de desarrollo terapéutico. El acuerdo está sujeto a acuerdos definitivos y aprobaciones regulatorias.
Psyence BioMed (NASDAQ: PBM)는 PsyLabs에 50만 달러의 후속 투자를 발표하며 사이키델릭 의약품 개발 파트너십을 강화했습니다. 이는 2024년 9월 PBM이 PsyLabs의 지분 11.13%를 인수한 계약을 기반으로 합니다.
이번 투자는 두 가지 주요 요소를 포함합니다:
- 제약 등급의 EU-GMP 인증을 받은 천연 유래 실로시빈 공급에 대한 독점 로열티 기반 지식재산권(IP) 라이선스 계약
- 제약 등급의 천연 유래 이보가인 전 세계 공급에 대한 독점 우선 구매권
이 파트너십은 물질 사용 장애(SUD), 특히 알코올 사용 장애(AUD) 치료제 개발에 중점을 둡니다. PsyLabs는 Psyence BioMed에 고품질 사이키델릭 화합물을 제공해 임상 파이프라인과 치료 개발 노력을 지원할 예정입니다. 이 계약은 최종 계약서와 규제 승인에 따라 진행됩니다.
Psyence BioMed (NASDAQ : PBM) a annoncé un investissement complémentaire de 500 000 USD dans PsyLabs, renforçant leur partenariat dans le développement de médicaments psychédéliques. Cela fait suite à leur accord de septembre 2024, où PBM a acquis une participation de 11,13 % dans PsyLabs.
L'investissement comprend deux éléments clés :
- Un accord exclusif de licence de propriété intellectuelle avec redevances pour la fourniture de psilocybine d'origine naturelle, de qualité pharmaceutique et conforme aux normes EU-GMP
- Un droit exclusif de premier refus pour la fourniture mondiale d'ibogaïne d'origine naturelle, de qualité pharmaceutique
Le partenariat vise à développer des traitements pour les troubles liés à l'usage de substances (SUD), y compris le trouble lié à l'usage d'alcool (AUD). PsyLabs fournira à Psyence BioMed des composés psychédéliques de haute qualité pour soutenir leur pipeline clinique et leurs efforts de développement thérapeutique. L'accord est soumis à la signature d'accords définitifs et aux approbations réglementaires.
Psyence BioMed (NASDAQ: PBM) hat eine Folgeinvestition von 500.000 USD in PsyLabs angekündigt und damit ihre Partnerschaft in der Entwicklung psychedelischer Medikamente gestärkt. Dies baut auf der Vereinbarung vom September 2024 auf, bei der PBM einen 11,13%igen Anteil an PsyLabs erworben hat.
Die Investition umfasst zwei wesentliche Bestandteile:
- Eine exklusive, lizenzgebührenpflichtige IP-Lizenzvereinbarung für die Lieferung von pharmazeutischem, EU-GMP-zertifiziertem, naturbasiertem Psilocybin
- Ein exklusives Vorkaufsrecht für die weltweite Lieferung von pharmazeutischem, naturbasiertem Ibogaïn
Die Partnerschaft konzentriert sich auf die Entwicklung von Behandlungen für Substanzgebrauchsstörungen (SUD), einschließlich Alkoholgebrauchsstörung (AUD). PsyLabs wird Psyence BioMed mit hochwertigen psychedelischen Verbindungen versorgen, um deren klinische Pipeline und therapeutische Entwicklungsbemühungen zu unterstützen. Die Vereinbarung steht unter dem Vorbehalt endgültiger Verträge und behördlicher Genehmigungen.
- Strategic vertical integration through secured supply of pharmaceutical-grade psychedelic compounds
- Exclusive worldwide rights for Ibogaine supply
- Expanded product pipeline into multiple therapeutic areas
- Strengthened partnership with established API manufacturer
- Deal subject to regulatory approvals and closing conditions
- Additional capital expenditure of $500,000
Insights
Psyence BioMed's
The significance lies not in the investment size but in the supply chain security it establishes for two distinct natural psychedelic compounds targeting substance use disorders (SUDs). For a micro-cap company (
Securing EU-GMP compliant, nature-derived compounds differentiates Psyence from competitors using synthetic alternatives, potentially offering both regulatory and therapeutic advantages. The focus on Alcohol Use Disorder (AUD) targets a substantial market with effective treatment options.
While this development strengthens Psyence's strategic positioning in psychedelic medicine development, investors should recognize this remains an early-stage play. The agreement is subject to definitive terms and regulatory approvals, with clinical validation of Ibogaine for SUDs still in preliminary phases. The vertical integration approach, however, provides operational advantages by eliminating future supply chain uncertainties as programs advance toward commercialization.
New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD
This new capital investment builds on the exclusive, royalty-bearing IP licensing agreement formalized between the two companies in September 2024, following an initial investment where Psyence BioMed acquired an
In parallel with this financial commitment, Psyence BioMed has secured an exclusive right of first refusal in respect of the worldwide supply of pharmaceutical-grade, nature-derived Ibogaine. Under this agreement, PsyLabs will grant Psyence BioMed a right of first refusal to acquire the exclusive rights to a dedicated supply of Ibogaine for evaluation in the treatment of SUD, including Alcohol Use Disorder (AUD). This exclusive partnership further strengthens Psyence BioMed's integrated development strategy, ensuring access to high-quality psychedelic compounds to support its growing clinical pipeline and diversification into multiple therapeutic areas.
Ibogaine, a naturally occurring psychoactive substance derived from the Tabernanthe iboga plant, has shown promise in early-stage research for its unique ability to interrupt SUDs, offering a novel approach to addiction treatment. Existing treatment options for SUDs and AUD remain limited in effectiveness, highlighting the urgent need for new solutions.
"We are thrilled to strengthen our partnership with PsyLabs through both our financial investment and this opportunity to acquire exclusive Ibogaine supply rights," said Dr. Neil Maresky, CEO of Psyence BioMed. "Ibogaine holds significant potential as part of a new wave of therapeutics targeting some of the most challenging conditions in mental health. With this agreement, we are well positioned to accelerate our research efforts and bring much-needed innovation to patients worldwide."
Tony Budden, Chief Executive Officer at PsyLabs, added: "This expanded collaboration with Psyence BioMed reflects our shared vision for advancing the science and development of nature-derived psychedelic medicines. By combining our manufacturing expertise with Psyence BioMed's clinical development capabilities, we are creating a powerful platform to explore the full potential of Ibogaine and psilocybin in addressing addiction and mental health disorders."
Additional details about PsyLabs are available at www.psylabs.life. An overview of the company's operations and manufacturing capabilities can be viewed in this video.
These strategic initiatives and investments align with Psyence BioMed's vision to develop a diversified pipeline of psychedelic-based therapeutics supported by strong supply chain partnerships and proprietary intellectual property, as the Company advances toward becoming a leading, vertically integrated psychedelic biotech company.
The follow-on investment shall be subject to the conclusion of a definitive right of first refusal agreement between the parties based on the salient terms already reduced to writing and other customary closing and suspensive conditions, including regulatory approvals (if any).
About Psyence BioMed:
Psyence BioMed is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. Psyence is dedicated to addressing unmet mental health needs, particularly in palliative care. The name 'Psyence' merges 'psychedelics' and 'science,' reflecting the company's commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
Learn more at www.psyencebiomed.com and on LinkedIn.
About PsyLabs
PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.
PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.
www.psylabs.life
Contact Information for Psyence Biomedical Ltd.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708
Investor Contact:
Michael Kydd
Investor Relations Advisor michael@psyencebiomed.com
Forward Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning.
Forward-looking statements in this communication include statements regarding the acquisition of exclusive Ibogaine supply rights, the growing of Psyence BioMed's clinical pipeline, and the diversification of its therapeutic areas. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of a definition right of first refusal agreement, that Psyence BioMed shall exercise its exclusive Ibogaine supply acquisition rights, and that the demand for psychedelic-assisted therapy will include the use of Ibogaine. There can be no assurance that the Company will continue to maintain compliance with Nasdaq's continued listing requirements.
There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, among others: (i) delays in the execution of the right of first refusal agreement; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed's business and changes in Psyence BioMed's capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's final prospectus (File No. 333-284444) filed with the Securities and Exchange Commission (the "SEC") on January 24, 2025 and other documents filed by Psyence BioMed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.
The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248469
FAQ
What is the value of Psyence BioMed's (PBM) new investment in PsyLabs?
What percentage stake does Psyence BioMed (PBM) own in PsyLabs?
What exclusive rights did PBM secure in the new PsyLabs agreement?
What medical conditions is Psyence BioMed (PBM) targeting with their psychedelic treatments?
What types of compounds will PsyLabs supply to Psyence BioMed (PBM)?
